The Current Role of Lymph Node Dissection in the Management of Renal Cell Carcinoma by Jamal, Joseph Edmund & Jarrett, Thomas William
Hindawi Publishing Corporation
International Journal of Surgical Oncology
Volume 2011, Article ID 816926, 5 pages
doi:10.1155/2011/816926
Review Article
TheCurrent Roleof Lymph Node Dissectionin
theManagementof RenalCellCarcinoma
JosephEdmundJamaland ThomasWilliamJarrett
Department of Urology, The George Washington University Medical Faculty Associates, 2150 Pennsylvania Avenue, NW,
Washington, DC 20037, USA
Correspondence should be addressed to Joseph Edmund Jamal,jjamal@mfa.gwu.edu
Received 1 February 2011; Accepted 3 April 2011
Academic Editor: Timothy M. Pawlik
Copyright © 2011 J. E. Jamal and T. W. Jarrett. This is an open access article distributed under the Creative CommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
The role of lymph node dissection remains controversial in the surgical management of renal cell carcinoma. Incidental renal
masses are being diagnosed at increasing rates due to the routine u s eo fC Ts c a n s .D e s p i t et h ei n c r e a s ei ni n c i d e n t a ld i a g n o s i s
of renal masses, 20% to 30% of patients present with metastatic disease. Currently, surgeons do not routinely perform lymph
node dissection unless there is gross evidence of lymphadenopathy, as patients without clinical evidence of lymphadenopathy
rarely have positive nodes at the time of surgery. Patients with metastatic disease to the regional lymph nodes have a poor overall
prognosis. However, some evidence supports a therapeutic beneﬁt of lymphadenectomy in these patients. Further, the staging
information gained from diagnosing lymph node involvement may allow for the use of new agents to treat metastatic disease and
eﬀect outcomes.
1.Introduction
The role of lymph node dissection (LND) remains contro-
versial in the surgical management of renal cell carcinoma
(RCC) [1–3]. To date, there is no deﬁnitive data which
indicates an overall survival advantage imparted by perform-
ing LND in patients with RCC. Additionally, a complete
LNDduringradicalnephrectomy(RN)addssigniﬁcanttime,
potential morbidity, and requires dissection of and around
the great vessels. What is clear is that in patients with renal
cell carcinoma without evidence of distant metastases, the
presence of lymph node-only metastases is associated with a
poor prognosis [4–10]. For this reason, identifying patients
at risk for positive lymph nodes at the time of surgical
treatment of their renal mass remains essential.
Recently, the ﬁrst prospective, randomized trial was
conducted by the European Organization for Research and
Treatment of Cancer (EORTC) to compare the long-term
results of radical nephrectomy alone (n = 389) versus
radical nephrectomy with complete lymphadenectomy (n =
383) for patients with clinically N0, M0 disease [1]. They
concluded that LND is not therapeutic in the routine
management of RCC, but nor did it increase the morbidity
of surgical management. This has spurred signiﬁcant debate
in the urologic oncology community [3, 11, 12]. Indeed,
this study was aimed at determining the long-term outcomes
in patients with clinically localized disease, and found that
70% of patients had pT1 or pT2 disease. The majority of
these patients were therefore unlikely to beneﬁt from LND
in the ﬁrst place. Therefore, it is important to emphasize
that although being a landmark study, it does not negate
the role for LND in RCC. With the recent availability of
new adjuvant agents, prospective adjuvant protocol studies
nearing completion, and neoadjuvant protocols currently
under study, the importance of LND may change, either as a
therapeuticorstagingprocedure.ThetopicofLNDtherefore
requires further discourse.
In clinical practice, the role of LND in the management
of RCC remains controversial due to variability of lymphatic
drainage ofthekidney,theabsenceoflymphatic involvement
in many patients with disseminated disease, and the lack
of deﬁnitive evidence of any survival beneﬁt imparted by
LND [1]. We address the current controversies regarding
the role of lymphadenectomy in the surgical management2 International Journal of Surgical Oncology
of renal tumors in this review. Ultimately, the therapeutic
beneﬁt of LND in RCC, whether it be beneﬁcial by itself or
in that it may be diagnostic of metastatic disease resulting in
initiation of adjuvant chemotherapy, may only be realized in
a select subset of patients.
2.Epidemiologyand Relevance
Renal cell carcinoma comprises 2% to 3% of malignant
neoplasms in adults. In the United States, 31,000 new cases
of RCC are diagnosed annually, and 11,900 patients die
of disease [13, 14]. There is a male-to-female ratio of
3:2 [13], and a 10% to 20% higher incidence in African
Americans [15]. The majority of cases of RCC are believed
to be sporadic, with only 4% familial according to National
Cancer Institute estimates. Approximately 20% to 30% of
patients with RCC present with metastatic disease [16], but
ranges from 3% in surgical series to 63.6% in autopsy series
[16]. Of these patients with metastatic disease, historically,
40% have distant metastases only without evidence of
lymph node involvement, 50% have both distant metastases
and lymph node involvement, and approximately 3–10%
present with lymph node involvement only [1, 17–19].
Additionally, one-third of patients with localized RCC will
eventuallydeveloprecurrenceorprogression.There hasbeen
downward stage migration, as well as increasing incidence
of RCC due to extensive utilization of cross-sectional
imaging.
In combination, the clinical stage and pathologic grade
of the tumor is highly predictive of positive lymph node
metastases. When LND is performed, a number of studies
have shown that positive lymph nodes have an independent
adverse eﬀect on outcome, irrespective of other variables
[20–22]. Patients with node-positive disease have 5-year
survival rates ranging from 5% to 35% [23].
3.TemplatesforLymphNodeDissection
Renal lymphatic drainage is variable, adding to the con-
troversy of performing LND at the time of RN. There is
currently no consensus on the anatomic extent of LND.
This makes it exceedingly diﬃcult to compare studies as
there is a clear lack of standardization. Further, many studies
do not delineate the template used for LND. A “standard”
LND for RCC on the left side includes the paraaortic and
preaortic nodes from the crus of the diaphragm to the
inferior mesenteric artery (IMA). On the right, a “standard”
LND includes the paracaval and precaval nodes from the
adrenal vein along the vena cava, also down to the level
of the IMA. An “extended” LND adds the interaortocaval
n o d e sd o w nt ot h eb i f u r c a t i o no ft h eg r e a tv e s s e l so nb o t h
sides, with the inclusion of retrocaval nodes for right-sided
primary tumors.
Crispen and colleagues recently examined their series of
patients with LND and evaluated the lymphatic drainage
patterns for recommendations for surgical templates [24].
Of 169 patients who ﬁt the criteria for LND, 64 (38%)
were found to have metastatic disease to their retroperi-
toneal lymph nodes, with the median of 6 lymph nodes
r e m o v e dw i t hL N D .F o rr i g h t - s i d e dt u m o r s ,t h ep r i m a r y
lymphatic drainage was the paracaval, precaval, retrocaval,
and interaortocaval lymph nodes. For left-sided tumors, the
primary lymphatic drainage was the paraaortic, preaortic,
retroaortic, and interaortocaval lymph nodes. They advocate
for a standard removal of all the lymphatic tissue in
these primary lymphatic landing zones. When examining
their data of patients with positive nodal disease, left-sided
tumors corresponded with 76% of left hilar and 62% of
paraaortic positive lymph nodes (of patients with positive
nodal disease). On the right side, patients with positive
lymph node involvement were found to occur in 57% of
paracaval and 43% of right hilar nodes. On both sides,
lymph nodes from the renal hilum were not always involved
in patients with nodal disease, supporting the argument
against merely sampling the renal hilar lymph nodes as
being suﬃcient. Based on these ﬁndings, they recommend
that when lymphadenectomy is performed in patients with-
out palpable disease, that left-sided disease LND includes
paraaortic and interaortocaval lymph nodes, and right-sided
disease LND includes paracaval and interaortocaval lymph
nodes.
Morbidity of LND has largely been found to be minimal
when compared to nephrectomy alone. Retrospective review
has shown little diﬀerence in morbidity of LND [25].
Additionally, the recent prospective EORTC 30881 trial also
showed no appreciable diﬀerencein morbidity between their
two randomized groups. They did not comment on the
additional length of time the LND added, nor the total
numberoflymphnodesremoved.Theyincludedmorbidities
such as bleeding >1 liter, pleural injury, infection, bowel
injury, embolism, and lymph ﬂuid drainage, and found
no signiﬁcant diﬀerences between patients who had LND
and those who did not. Siminovitch and colleagues [26]
performed a direct comparison of extended, hilar, and
regional LND templates. They found no diﬀerences in
morbidity or survival rates between the three diﬀerent LND
templates. Regardless, LND remains a complex procedure,
and carries risk for serious intraoperative complications.




Signs of lymphadenopathy or evidence of locally advanced
disease on cross-sectional imaging, warrants LND. Palpable
lymphadenopathy, or evidence of bulky lymph nodes with
laparoscopy, at the time of RN can be indications for
LND. Unfortunately, radiographic lymphadenopathy only
modestly correlates with metastatic involvement, with 32%–
43%ofnodes>1cmharboring cancer[27,28].Otherstudies
have shown that 16%–42% of lymph nodes suspicious
on are falsely positive [1, 18, 29]. Many of these nodes
are inﬂammatory in nature, and therefore no beneﬁt is
imparted by theirremoval. The diﬃcultieslie in determining
the lymphatic drainage patterns of each kidney, which
lymph nodes are potentially positive, and to what extent a
lymphadenectomy should be performed.International Journal of Surgical Oncology 3
Nomograms have been developed to aid in risk stratiﬁ-
cation. One nomogram had 78% accuracy by incorporating
patient age, radiographic tumor size, and symptoms [28].
Another preoperative nomogram, which included 4844
patients, found a concordance index of 0.76 when including
symptoms at presentation, radiographic lymphadenopathy,
tumorsize, andhematuria [30].Neitherof thesenomograms
have gained widespread acceptance.
Crispen and colleagues evaluated the performance of
LND in high-risk clear cell RCC patients between 2002 and
2006 [24]. They had previously identiﬁed ﬁve intraoperative
pathological features which were considered high-risk for
nodal metastases, and performed LND if at least two of these
risk factors were present intraoperatively. These were nuclear
grade 3 or 4, sarcomatoid component, tumor size ≥10cm,
tumor stage pT3 or pT4, and coagulative tumor necrosis. Of
169RNsthathad2high-riskintraoperativefactors,63(38%)
had nodal metastases.
Others have novel approaches to expanding indications
for LND. Bex and colleagues evaluated the role of sentinel
node detection in patients with RCC [31]. Previous series
indicate that 58–95% of patients with lymph node disease
have associated hematogenous spread [32, 33], prompting
Bex and colleagues to assess the feasibility of identifying a
sentinel node to aid in staging. Eight patients with cT1 cN0
cM0 RCC had their tumors injected (percutaneously under
ultrasound guidance) with a radionuclide tracer, 99mTc-
nanocolloid. Both lymphoscintigraphy and SPECT/CT were
performedtodeterminetheanatomic locationofthesentinel
node, as there is variable lymphatic drainage of the kidney.
Surgery was then performed the following day utilizing
intraoperative gamma probes to identify the radioactive
nodes. Of the eight patient tumors injected, six patients were
found to have identiﬁable sentinel nodes on scintigraphy. In
two patients, no identiﬁable drainage of the radiotracer was
found.Inthissmall study, anidentiﬁablesentinel nodecould
befoundin75%oftumors.Theauthorssuggestthatthismay
be helpful in patients in which biopsy of the sentinel node
could clarify the extent of lymphatic involvement, which
could have diagnostic and therapeutic implications [31].
Ming and colleagues evaluated the utility in performing
frozen section analysis of enlarged lymph nodes during
RN for RCC [34]. They performed frozen section analysis
on lymph nodes >1cm, before undertaking an extended
lymphadenectomy. Of 702 consecutive patients, 114 had
evidence of enlarged lymph nodes or palpably enlarged
nodes and underwent frozen section analysis. On ﬁnal
pathology,theyfound that78patients(68.4%)with enlarged
lymph nodes did not harbor cancer while 36 (31.6%) did
have nodal metastases. Of these 36 patients with nodal
disease on ﬁnal pathology, 32 had positive ﬁndings on
frozen section, resulting in positive predictive value of 100%
and negative predictive value of 95%. The study concludes
that it would be reasonable to avoid LND in patients with
clinically localized RCC in whom frozen section analysis
of enlarged lymph nodes reveals no evidence of malignant
disease. However, this does not indicate any therapeutic
advantage to the procedure in patients with lymph node
disease.
5.Outcomesof LND
Patients with clinically localized RCC have not been shown
to beneﬁt from routine LND [1]. The EORTC 30881 trial
conﬁrmed that after appropriate clinical staging, in patients
with clinical N0M0 disease, the incidence of unsuspected
lymph-node metastases was only 4.0%. When compared
with nephrectomy alone, they showed no advantage to
performing LND on patients with clinically localized disease
with regards to overall survival, local regional progression,
or distant progression. Of the 346 patients in whom LND
was performed, 51 had palpably enlarged lymph nodes at the
time of surgery. Of these, only 10 patients (20%) had lymph
node metastases. Remarkably, of the 311 remaining patients
without palpable nodes, only 4 patients (1%) were shown
to have metastatic disease to their lymph nodes (P<. 001).
The potential beneﬁts of staging for these patients are also
minimal. These statements are especially true for more low-
risk disease (T1-2, N0, M0).
T h em o r ed i ﬃcult patient population to address is those
with clinically localized, high-risk disease (T3-4, N0, M0).
The root of this diﬃculty stems from the fact that there is
substantial risk of hematogenous dissemination of disease,
and relatively low risk of node-only involvement. The ther-
apeutic beneﬁt of LND in these patients is questionable at
best. As previously discussed, Blute and colleagues identiﬁed
5 risk factors (including clinical stage T3-4) for lymph
node metastases. The presence of at least 2 risk factors
was associated with a 15-fold higher incidence of regional
lymph node involvement. Although diﬃcult to implement,
this isreasonable approach forthese patientsin whom occult
disease may be cured.
Patients who present with clinical nodal disease should
have LND performed. It is relatively infrequent for patients
to present with isolated positive nodes, without distant
metastases, but is estimated to occur in 3% to 10% of
cases [1, 17–19]. It is essential, therefore, to accurately rule
out distant metastatic disease if one suspects lymph node
involvement only. Survival of these patients improves when
LND is performed compared to nephrectomy alone [32].
Further, the overall survival of these patients who undergo
LND with radical nephrectomy is far superior to patients
who present with distant metastases, and in fact more closely
approximates the survival of patients with T3, N0, M0
disease [35, 36]. Giuliani and colleagues showed that 5-year
survival inpatientswith lymphnode onlydisease was47.9%,
compared with 7% for patients with distant metastases. An
extended lymph node dissection, as described previously, is
recommended in these patients.
Patients with metastatic disease may beneﬁt only slightly,
if at all, from LND at the time of nephrectomy. Nodal metas-
tases are poorly responsive to immunotherapy, so removal
of grossly positive nodes is reasonable. Although extended
lymphadenectomy may theoretically be beneﬁcial, there is
no evidence to support this, and lymphadenectomy must be
balanced with the patient’s comorbidities and performance
status. A useful, evidence-based algorithm was oﬀered by
Godoyandcolleagues[16]thatcanbeutilizedinthedecision
to perform LND at the time of radical nephrectomy. With4 International Journal of Surgical Oncology
the advent of new tyrosine kinase inhibitors and cytokines,
the value of LND in patients with metastatic disease may
increase in the near future, either as adjuvant or neoadjuvant
therapy.
6.CurrentStateofTargetedTherapies
Previously, systemic treatment of patients with metastatic
RCC was limited to cytokine therapy with interleukin-
(IL-) 2 or interferon- (IFN-) α, because of mRCC’s gen-
eral resistance to chemotherapy. High-dose IL-2 remains
the only treatment to produce durable remissions, and
it should be considered in healthy, appropriately chosen
candidates as adjuvant therapy. New targeted therapies have
been developed through genetic studies of familial von
Hippel Lindau disease. Speciﬁcally, molecular cell signaling
pathways involving the vascular endothelial growth factor
(VEGF) and the mammalian target of rapamycin (mTOR)
pathways have been targeted with tyrosine kinase inhibitors
(TKIs) and mTOR inhibitors, respectively.
Node-onlymetastatic RCCis rare, and no speciﬁc dataof
thesepatientstreated with targetedtherapiescurrently exists.
Instead, we suggest treating these patients similar to those
having a solitary metastasis. Based on current data, sunitinib
(TKI) is justiﬁed as a ﬁrst-line standard of care for patients
with clear cell RCC [37, 38]. Another ﬁrst-line therapy for
clearcellRCCiscombinationtherapywithbevacizumabplus
interferon-α based on recent phase III data. Patients with
nonclear cell metastatic RCC should be enrolled in clinical
trials; however, they have been treated with TKIs, mTOR
inhibitors, and even chemotherapy with gemcitabine and
cisplatin for metastatic sarcomatoid RCC.
Currently, randomized controlled studies have been
initiated to determine the current role and optimal tim-
ing of removal of the primary tumor in patients with
primary metastatic disease, since historically cytoreductive
nephrectomy followed by cytokine treatment had better
overall survival than cytokine therapy alone. Therefore,
participation in a clinical trial is currently considered as
the best management of metastatic RCC patients presenting
with a resectable primary and synchronous metastases. In
patients with more advanced disease, anecdotal evidence
has suggested that neoadjuvant targeted therapies disease
canimprovefeasibility ofcytoreductivenephrectomy, reduce
nodal involvement, and facilitate lymphadenectomy by
improving the planes of dissection [39]. We look forward to
the further development of a targeted therapy regimen for
patients with metastatic disease.
7.Conclusion
Lymphadenectomy at the time of radical nephrectomy is
rarely performed and is not supported in the majority of
patients with renal tumors, especially with the downward
stage migration of disease. It does not appear to confer a
survival advantage in patients who have clinically localized
disease. However, LND at the time of nephrectomy is not
associated with signiﬁcantly increased morbidity [1]a n di s
warranted if there is suﬃcient clinical suspicion on staging
CT, or if bulky lymphadenopathy is found at the time of
surgery. Although lymphadenectomy undoubtedly improves
the accuracy of staging and provides better prognostic
information, there is little impact on progression-free or
overall survival in patients with clinically localized disease.
Risk factors may increase the likelihood of lymph node
metastases, and may be a way to better determine patients
at risk for nodal involvement. Future studies with novel
targeted therapies may increase the indications for LND
further.
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